Using RNA Analytics, Bioinformatics, and Machine Learning/AI
AMPEL Genomic Platform (AGP®) and
genomic blood or biopsy tests for patients:
Evaluate disease status
Identify molecular pathways
Predict drug options
Precise Clinical Care Solutions
AMPEL Genomic Platform (AGP®), Bioinformatic Tools and Machine Learning Algorithms (AI/ML)
Create A Genomic Fingerprint
Comprehensive RNA analytics of gene expression from blood or biopsy to determine disease activity, molecular pathways and drug options.
Analyze The Fingerprint With ML/AI
Covers >95% of all known genes and is disease agnostic.
Provide Decision Making Support
Identification of patient’s immune status, provides decision support for most appropriate treatment options.
Market ready and Reproducible
First-in-class CLIA-certified gene-based Lab Developed Test (LDT).
Lead product LuGENE® expected Q2 2023. DermaGENE® expected Q1 2024.
Products for other indications available for partnering.
coverage of all known genes and is disease agnostic
autoimmune and normal patient gene expression profiles with rich clinical information – world’s largest for Lupus
technology patents filed & pending with the freedom to operate
pharma customers validate the technology
additional autoimmunity products in development